FDA PMA FDA Class 3 Approved 🇺🇸 United States

Aortic Valve, Prosthesis, Percutaneously Delivered

PMA: P130009 · Decision Jun 16, 2014
Classifications
1
FEI Numbers
24
Registration Numbers
24

Basic Information

Device Name
Aortic Valve, Prosthesis, Percutaneously Delivered
Trade Name
EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE AND ACCESSORIES
PMA Number
P130009
Device Class
FDA Class 3
Product Code
NPT
Generic Name
Aortic valve, prosthesis, percutaneously delivered
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
Approved
Decision Code
APPR
Decision Date
June 16, 2014
Date Received
May 2, 2013
Expedited Review
N
Docket Number
14M-0874

Advisory Committee Statement

APPROVAL FOR THE SAPIEN XT TRANSCATHETER HEART VALVE (THV), MODEL 9300TFX, AND ACCESSORIES. THIS DEVICE IS INDICATED FOR RELIEF OF AORTIC STENOSIS IN PATIENTS WITH SYMPTOMATIC HEART DISEASE DUE TO SEVERE NATIVE CALCIFIC AORTIC STENOSIS (AORTIC VALVE AREA <=1.0 CM2 OR AORTIC VALVE AREA INDEX <=0.6 CM2/M2, A MEAN AORTIC VALVE GRADIENT OF >= 40 MMHG, OR A PEAK AORTIC-JET VELOCITY OF >= 4.0 M/S), AND WITH NATIVE ANATOMY APPROPRIATE FOR THE 23, 26, OR 29 MM VALVE SYSTEM, WHO ARE JUDGED BY A HEART TEAM, INCLUDING A CARDIAC SURGEON, TO BE AT HIGH OR GREATER RISK FOR OPEN SURGICAL THERAPY (I.E., SOCIETY OF THORACIC SURGEONS OPERATIVE RISK SCORE >=8% OR AT A >=15% RISK OF MORTALITY AT 30 DAYS).

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
NPT Aortic Valve, Prosthesis, Percutaneously Delivered